WASHINGTON — A judge’s decision to suspend the Food and Drug Administration’s approval of an abortion pill could have massive impacts for the pharmaceutical industry, but its largest lobbying association is staying on the sidelines.
PhRMA, which is the top-spending lobbying group in the health care sector and is known to be litigious itself, still hasn’t put out a press release on the decision made by a judge in Texas on Friday — despite the possibility that the decision could destabilize the sanctity of the FDA approval process entirely.
Instead, PhRMA is sending a restrained statement to reporters upon request:
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect